Prestige Consumer Healthcare Q2 revenue beats on acquisition boost
PBH•Prestige Consumer Healthcare’s second-quarter revenue rose 22.7% to $336.31 million, topping the $329.13 million consensus, while adjusted diluted EPS increased to $1.13 from $1.07. The company cut its fiscal 2027 revenue and adjusted EPS outlook, citing Clear Eyes supply issues.
1. Quarterly results
Second-quarter revenue increased 22.7% to $336.31 million, above the $329.13 million analyst consensus. Adjusted diluted EPS rose to $1.13 from $1.07 a year earlier. Revenue growth reflected contributions from the Breathe Right and LaCorium acquisitions in North American and International segments.
2. Outlook reduced
Prestige Consumer Healthcare lowered its fiscal 2027 revenue outlook to $1.28 billion-$1.29 billion and its adjusted diluted EPS forecast to $4.48-$4.55. The company expects Clear Eyes supply constraints to weigh on second-half revenue; lower Clear Eyes sales and order timing headwinds contributed to a decline in organic revenue. Hydralyte posted double-digit sales growth in the International segment.
